Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.62 USD | -0.47% |
|
-2.94% | -2.98% |
Feb. 07 | AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo | DJ |
Feb. 07 | US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections | RE |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 16.27B | 9.62B | 21.98B | 31.37B | 2.12B | |||||
Depreciation & Amortization - CF | 1.36B | 1.32B | 1.4B | 1.42B | 1.52B | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 4.61B | 3.44B | 3.7B | 3.61B | 4.73B | |||||
Depreciation & Amortization, Total | 5.97B | 4.76B | 5.1B | 5.03B | 6.26B | |||||
(Gain) Loss From Sale Of Asset | - | - | - | - | - | |||||
(Gain) Loss on Sale of Investments - (CF) | -8.23B | -6M | - | - | - | |||||
Asset Writedown & Restructuring Costs | 2.99B | 2.07B | 363M | 586M | 3.44B | |||||
Stock-Based Compensation (CF) | 718M | 756M | 1.18B | 872M | 525M | |||||
Net Cash From Discontinued Operations | - | 3.82B | -343M | - | 15M | |||||
Other Operating Activities, Total | -1.1B | -6.33B | -8.51B | -4.14B | -1.48B | |||||
Change In Accounts Receivable | -742M | -1.25B | -3.81B | 261M | 347M | |||||
Change In Inventories | -1.05B | -736M | -1.12B | 592M | -1.17B | |||||
Change In Accounts Payable | -564M | 353M | 1.24B | 1.19B | -300M | |||||
Change in Other Net Operating Assets | -1.68B | 1.36B | 16.5B | -6.5B | -1.05B | |||||
Cash from Operations | 12.59B | 14.4B | 32.58B | 29.27B | 8.7B | |||||
Capital Expenditure | -2.18B | -2.25B | -2.71B | -3.24B | -3.91B | |||||
Cash Acquisitions | -10.86B | - | - | -23B | -43.43B | |||||
Sale (Purchase) of Intangible assets | -418M | -539M | - | - | - | |||||
Investment in Marketable and Equity Securities, Total | 9.3B | -1.67B | -19.52B | 6.68B | 15.24B | |||||
Other Investing Activities, Total | 206M | 192M | -318M | 3.77B | -180M | |||||
Cash from Investing | -3.94B | -4.27B | -22.55B | -15.78B | -32.28B | |||||
Short Term Debt Issued, Total | 19.01B | 12.35B | - | 3.89B | 7.69B | |||||
Long-Term Debt Issued, Total | 4.94B | 5.22B | 997M | - | 30.83B | |||||
Total Debt Issued | 23.95B | 17.57B | 997M | 3.89B | 38.52B | |||||
Short Term Debt Repaid, Total | -8.38B | -26.33B | -96M | -4.11B | -3M | |||||
Long-Term Debt Repaid, Total | -6.81B | -4B | -2B | -3.3B | -2.57B | |||||
Total Debt Repaid | -15.18B | -30.33B | -2.1B | -7.41B | -2.57B | |||||
Issuance of Common Stock | 394M | 425M | - | - | - | |||||
Repurchase of Common Stock | -8.86B | - | - | -2B | - | |||||
Common Dividends Paid | - | -8.44B | -8.73B | -8.98B | -9.25B | |||||
Common & Preferred Stock Dividends Paid | -8.04B | - | - | - | - | |||||
Common & Preferred Stock Dividends Paid | -8.04B | -8.44B | -8.73B | -8.98B | -9.25B | |||||
Other Financing Activities, Total | -735M | 11.12B | 16M | -335M | -632M | |||||
Cash from Financing | -8.48B | -9.65B | -9.82B | -14.83B | 26.07B | |||||
Foreign Exchange Rate Adjustments | -32M | -8M | -59M | -165M | -40M | |||||
Miscellaneous Cash Flow Adjustments | -1M | - | - | - | - | |||||
Net Change in Cash | 125M | 475M | 159M | -1.52B | 2.45B | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 1.59B | 1.64B | 1.47B | 1.44B | 2.22B | |||||
Cash Income Tax Paid (Refund) | 3.66B | 3.15B | 7.43B | 7.87B | 3.15B | |||||
Levered Free Cash Flow | 18.42B | 10.5B | 30.86B | 24.96B | 1.02B | |||||
Unlevered Free Cash Flow | 19.4B | 11.41B | 31.66B | 25.73B | 2.4B | |||||
Change In Net Working Capital | -5.89B | -2.33B | -11.29B | 1.32B | 3.78B | |||||
Net Debt Issued / Repaid | 8.76B | -12.76B | -1.1B | -3.52B | 35.94B |